Panacea Index Logo

Command Palette

Search for a command to run...

Six-minute walking test and long term prognosis in patients with asymptomatic aortic valve stenosis.

International journal of cardiology
January 1, 1970
Per Ejlstrup Sigvardsen et al. (8 authors)
Journal ArticleMulticenter StudyHuman Study
Study Details

Study Goal

The researchers aimed to determine whether the 6-minute walking test (6MWT) could predict all-cause and cardiovascular mortality in asymptomatic patients with aortic valve stenosis.

Results Summary

The study found that shorter walking distances (≤390m) during the 6MWT were associated with higher risks of all-cause and cardiovascular mortality, while longer distances (>465m) were linked to no cardiovascular deaths. Each additional 100m walked reduced all-cause mortality risk by 35%.

Population

Asymptomatic patients with aortic valve stenosis (peak velocity >2.5m/s and left ventricular ejection fraction >50%; 85 males; aged 72±8 years).

Effective Dosage

Not applicable (6MWT performance assessed, not a dosage).

Duration

Median follow-up of 5.5 years (IQR 4.5-6.3).

Interactions

None mentioned

Extracted Claims (7)
InterventionDirectionEndpointPopulationDosageImpactClaim #
6-minute walking test (6MWT)
increase
all-cause mortality
asymptomatic patients with aortic valve stenosis
-
is an independent predictor of
#1
6-minute walking test (6MWT)
increase
cardiovascular mortality
asymptomatic patients with aortic valve stenosis
-
is an independent predictor of
#2
short distance in 6MWT (≤390m)
increase
all-cause mortality
asymptomatic patients with aortic valve stenosis
HR: 2.44; 95% CI: 1.05-5.67; p=0.04
were at higher risk of
#3
short distance in 6MWT (≤390m)
increase
cardiovascular mortality
asymptomatic patients with aortic valve stenosis
HR: 6.12; 95% CI: 1.18-31.83; p=0.03
were at higher risk of
#4
every 100m covered in 6MWT
decrease
risk of all-cause mortality
asymptomatic patients with aortic valve stenosis
by 35% (HR: 0.65; 95% CI: 0.43-0.99; p=0.04)
decreased
#5
long distance in 6MWT (>465m)
no change
cardiovascular deaths
asymptomatic patients with aortic valve stenosis
-
did not experience
#6
6-minute walking test (6MWT)
neutral
echocardiographic evaluation
asymptomatic patients with aortic valve stenosis
-
is of incremental value to
#7
Abstract

BACKGROUND: Management of asymptomatic patients with aortic valve stenosis is challenging due to the elusive relationship between symptomatic status and hemodynamic parameters in addition to the occurrence of cardiovascular death. The 6-minute walking test (6MWT) reflects overall hemodynamic function and could contribute to risk assessment in such patients. METHODS AND RESULTS: One hundred sixteen asymptomatic patients (peak velocity>2.5m/s and left ventricular ejection fraction >50% assessed by echocardiographic screening; 85 males; aged 72±8years) underwent clinical workup, transthoracic echocardiography and a 6MWT. The mean distance covered by patients able to perform the 6MWT (n=107) was 422±90m. Patients were grouped in tertiles according to distance covered in the 6MWT: Short, intermediate and long distance patients. During a median follow-up of 5.5years (IQR 4.5-6.3), 29 (25%) patients died, 10 (9%) from cardiovascular causes. Multivariate analysis revealed that short distance patients (≤390m) were at higher risk of all-cause mortality (HR: 2.44; 95% CI: 1.05-5.67; p=0.04) and cardiovascular mortality (HR: 6.12; 95% CI: 1.18-31.83; p=0.03). For every 100m covered, the risk of all-cause mortality decreased by 35% (HR: 0.65; 95% CI: 0.43-0.99; p=0.04). Long distance patients (>465m) did not experience cardiovascular deaths during follow-up. CONCLUSIONS: In asymptomatic patients with aortic valve stenosis, the 6MWT is an independent predictor of all-cause and cardiovascular mortality. It is of incremental value to the echocardiographic evaluation, suggesting that the 6MWT might be useful to guide clinical follow-up intervals and treatment strategy.

Medical Subject Headings (MeSH)
AgedAged, 80 and overAortic Valve StenosisAsymptomatic DiseasesFemaleFollow-Up StudiesHumansMaleMiddle AgedPrognosisProspective StudiesRisk FactorsTime FactorsWalkingWalking Speed
Study Links
Quality Scores
SafetyNot Assessed
Efficacy85/10
Quality80/10
Citation Metrics
Total Citations5
Citations/Year0.6
Relative Citation Ratio0.25
NIH Percentile12.9%
Research Impact Scores
APT Score0.25
Weight Score1.57
Normalized Score0.70
Related Supplements